Please login to the form below

Not currently logged in
Email:
Password:

Abeona Therapeutics appoints new additions to board of directors

Stefano Buono and Richard Van Duyne join the biopharma

AbeonaAbeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the appointment of Stefano Buono and Richard Van Duyne.

Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.

He said: “Abeona’s ambitious gene and cell therapies have the promise to bring treatments to patients for whom there are currently no treatment options available.

“Its mission to bring relief and an extended, better quality of life to patients, many of whom are children, is closely aligned with my own values, and I am happy to be able to contribute to the company.”

Van Duyne, on the other hand, has previously held executive-level business development positions, which led him to serve as global head of business development for Daiichi Sankyo.

He said: “I am excited to be joining Abeona’s board at such a time of momentum for the company and the gene therapy space as a whole.

“I believe Abeona’s pipeline has significant potential to bring transformative therapies to patients with devastating, life-threatening diseases.”

31st May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics